CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments. "We are very optimistic about the prospects of our ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...

Greenwich LifeSciences (GLSI), focused on its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy to prevent breast ...

Published in Clinical Cancer Research, results of a VHIO-led study underscore the potential of the RAD51 biomarker in ...

Common symptoms like blood in urine or frequent urination should prompt a visit to a urologist. Early evaluation is crucial for effective bladder cancer management. Consult a urologist promptly for ...

Shares of Phio Pharmaceuticals Corp. surged 330% Monday afternoon, reaching their highest levels in nearly eight months, to ...

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...

Neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to better survival outcomes ...

Falls are frequently reported within the HSE. The Irish Longitudinal Study on Ageing(TILDA) found that 40% of over 50 s experience a fall in a two year period, with 20% requiring hospital attendance ...